Key Points
- Adar1 Capital Management bought 120,804 Rallybio shares on May 4 at an average $13.97/share for $1,687,631.88 (and added 35,101 shares on May 5), increasing its direct stake to 744,683 shares — a 19.36% ownership increase.
- Rallybio has a market cap of $77.02 million, a 52‑week range of $2.16–$15.31 and negative earnings (PE -5.69), with roughly 90.34% of the stock held by institutions and a consensus analyst rating of "Sell" despite a recent "Hold" from one outlet.
Rallybio Corporation (NASDAQ:RLYB - Get Free Report) major shareholder Adar1 Capital Management, Llc purchased 35,101 shares of the business's stock in a transaction that occurred on Tuesday, May 5th. The stock was bought at an average cost of $14.00 per share, for a total transaction of $491,414.00. Following the completion of the acquisition, the insider directly owned 779,784 shares of the company's stock, valued at $10,916,976. This represents a 4.71% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.
Adar1 Capital Management, Llc also recently made the following trade(s):
- On Monday, May 4th, Adar1 Capital Management, Llc purchased 120,804 shares of Rallybio stock. The stock was bought at an average cost of $13.97 per share, for a total transaction of $1,687,631.88.
Rallybio Stock Performance
Shares of NASDAQ:RLYB opened at $14.56 on Thursday. The stock has a market capitalization of $77.02 million, a price-to-earnings ratio of -5.69 and a beta of -1.10. Rallybio Corporation has a 1-year low of $2.16 and a 1-year high of $15.31. The company's fifty day moving average is $9.01 and its two-hundred day moving average is $6.58.
Rallybio (NASDAQ:RLYB - Get Free Report) last issued its earnings results on Monday, March 16th. The company reported ($1.03) earnings per share for the quarter, topping analysts' consensus estimates of ($1.04) by $0.01. The company had revenue of $0.22 million for the quarter, compared to analysts' expectations of $0.10 million. Rallybio had a negative net margin of 1,046.39% and a negative return on equity of 56.93%.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen raised shares of Rallybio to a "hold" rating in a report on Saturday, March 28th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Rallybio has a consensus rating of "Sell".
Check Out Our Latest Stock Report on RLYB
Hedge Funds Weigh In On Rallybio
Institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC grew its position in shares of Rallybio by 16.9% during the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company's stock worth $573,000 after acquiring an additional 120,892 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company's stock worth $170,000 after acquiring an additional 2,996 shares during the last quarter. Citadel Advisors LLC grew its position in shares of Rallybio by 576.1% during the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company's stock worth $219,000 after acquiring an additional 373,821 shares during the last quarter. Susquehanna International Group LLP grew its position in shares of Rallybio by 485.9% during the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company's stock worth $68,000 after acquiring an additional 113,031 shares during the last quarter. Finally, XTX Topco Ltd grew its position in shares of Rallybio by 64.6% during the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company's stock worth $67,000 after acquiring an additional 38,205 shares during the last quarter. Institutional investors own 90.34% of the company's stock.
About Rallybio
(
Get Free Report)
Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company's scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio's pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.
Among Rallybio's lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
